Ultralife Reports Q4 Loss Due to Impairment, Highlights Strong Operational Growth and Backlog
Summary
Ultralife reported a Q4 net loss due to a $12.2M non-cash impairment charge from rebranding, but showed strong operational growth, increased Adjusted EBITDA, and a 22% rise in backlog.
Key Events
-
Q4 Net Loss Driven by Impairment
Reported a GAAP net loss of ($7.4) million, or ($0.45) per share, primarily due to a $12.2 million non-cash intangible asset impairment charge related to a comprehensive rebranding initiative.
-
Strong Revenue Growth
Achieved a 10.6% increase in Q4 revenue to $48.5 million, driven by a 15.1% rise in Battery & Energy Products sales.
-
Adjusted EBITDA Improvement
Adjusted EBITDA increased by 46% to $5.7 million, reflecting improved underlying operational profitability despite the one-time charges.
-
Significant Backlog Increase
Backlog grew by 22% sequentially to $110.2 million, signaling strong future demand and order flow.
Analysis
Ultralife Corporation reported a net loss for Q4 2025, primarily driven by a significant $12.2 million non-cash intangible asset impairment charge related to a strategic rebranding initiative. Despite the GAAP loss, the company demonstrated strong operational performance with a 10.6% increase in revenue, improved gross margins, and a 46% rise in Adjusted EBITDA. Furthermore, backlog grew by 22% to $110.2 million, indicating robust future demand. Management expressed confidence in 2026 for sustainable profitable growth and debt reduction, supported by operational realignments and a new tax credit. Investors should focus on the underlying operational improvements and future outlook rather than solely on the one-time non-cash charge.
At the time of this filing, ULBI was trading at $5.73 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $95.4M. The 52-week trading range was $4.07 to $9.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.